Navigation Links
Sunesis Pharmaceuticals to Present at Healthcare Investor Conferences in March
Date:3/13/2008

SOUTH SAN FRANCISCO, Calif., March 13 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Daniel Swisher, Sunesis' Chief Executive Officer and President, will provide a corporate overview at two upcoming investor conferences in March.

-- Mr. Swisher will speak at the Cowen and Company 28th Annual Health Care

Conference at 8:45 a.m. Eastern Time on Tuesday, March 18, 2008 at the

Boston Marriott Copley Place in Boston, Mass.

-- On Thursday, March 20, 2008, Mr. Swisher will present at the Lehman

Brothers Eleventh Annual Global Healthcare Conference at 12:45 p.m.

Eastern Time in Miami, Fla.

Interested parties may access a webcast of each the presentations by visiting the Sunesis website at http://ir.sunesis.com. A replay of the webcasts will be archived on the "Calendar of Events" page in the Investors and Media section of the Sunesis website for two weeks.

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For further information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.


'/>"/>
SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
2. Sunesis Pharmaceuticals Reports New Option Grants Under NASDAQ Marketplace Rule 4350
3. Sunesis Pharmaceuticals SNS-595 Shows Clinical Activity in Patients With Relapsed or Refractory Acute Leukemias; Data Presented in Oral Session at 49th Annual Meeting of the American Society of Hematology
4. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
5. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
6. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
7. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
8. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
9. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
10. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
11. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... and CARTERSVILLE, Georgia (PRWEB) , ... August 16, 2017 , ... ... the fastest growing companies in the U.S. for the second year in a row. ... growth over the past three years. , “To be on the list once is ...
(Date:8/16/2017)... Atlanta, GA (PRWEB) , ... August 16, 2017 , ... ... the new Inc. 5000. The company ranked #4429 on the newly released, 36th annual ... The list represents a unique look at the most successful companies within the American ...
(Date:8/16/2017)... ... 16, 2017 , ... In a recent survey, eighty-two percent of women reported ... fact, cellulite can't always be eliminated by diet and exercise alone, and now for ... physicians nationwide. Dr. Kenneth Rothaus has recently added Cellulaze™ to his practice ...
(Date:8/16/2017)... Long Island, NY (PRWEB) , ... August 16, 2017 , ... ... assist with IV starts and blood draws. By broadly deploying AccuVein devices, Maury Regional ... technology takes much of the guesswork out of a needle stick and more importantly, ...
(Date:8/16/2017)... ... August 16, 2017 , ... LabRoots , the leading provider ... the world, is excited to announce Andrew Ly as the winner of the LabRoots ... textbook costs. , Ly, who is in his third year at the University ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... 15, 2017  AOTI Inc. announced today that its fully owned ... recently opened a New York City Office in Yonkers, ... unique Topical Wound Oxygen (TWO 2 ) homecare therapy. This new ... for Health Care (ACHC) under the company,s DMEPOS accreditation for Home/Durable ... Advanced ...
(Date:8/8/2017)... Second-quarter 2017 revenues of $876 million and ... operations Second-quarter 2017 Branded ... Second-quarter 2017 Sterile Injectables ... Second-quarter 2017 adjusted diluted earnings per ... $0.93 Second-quarter 2017 reported ...
(Date:8/7/2017)... , Aug. 7, 2017  Endo International plc ... reached agreements to resolve virtually all known U.S. mesh ... discussions to resolve the known remaining U.S. claims at ... payments beginning in the fourth quarter of 2017 and ... of its second quarter 2017 results, the Company intends ...
Breaking Medicine Technology: